In an exclusive interview, CNBC’s Jim Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories, about the Company’s growth plans, drug prices and the future of cancer research.
Charles River Laboratories is the first full-service contract research organization (CRO) to join the U.K.-based, international Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute and Consortium is a collaborative matchmaking service established in 2015 that connects academic research centers, pharmaceutical companies and the industry’s leading scientists in an effort to accelerate research and improve outcomes for patients.
For James Foster, CEO of what is already the second largest Massachusetts-based company in the drug development industry by headcount, Charles River Laboratories, continued growth is a necessity. That mentality has spurred seven acquisitions since 2014.
Widespread adoption of biomarkers has been impeded by a lack of consistent validation methodology and an unclear regulatory environment. If a biomarker is being used to determine the safety and/or effectiveness of a drug, it should be validated rigorously. Here are five key points to consider.
Although cancer’s status as the leading therapeutic area for drug candidates looks set to remain unrivaled for the foreseeable future, the emphasis on each stage of drug discovery and development tends to fluctuate according to each drug maker’s pipeline. Aidan Synnott from Charles River discusses preclinical cancer drug development in Drug Discovery & Development.
Business isn't always perfect. In Crain's "If I Knew Then…" column, Jim Foster discusses what he's learned from his mistakes, including the importance of working with great people.
Hua Wang was recently nominated for Bioanalysis Zone's New Investigator Award. Hua is a member of our team in Ohio, and joined Charles River as part of WIL Research this year. He is an outstanding scientist who has contributed significantly to a variety of bioanalysis projects to support drug development programs.
Charles River is conducting new studies using animal models to give insight into therapeutic strategies where pharma companies expect to see the most success. These advances in research models are making “moonshots” a reality for cancer patients. Dr. Joseph Murphy from Charles River discusses more on Outsourcing-Pharma.com.
A rapid increase in the number of companies working on development and registration of biosimilars has created a significant market for outsourced services specific to these products. Biosimilar developers turn to contract organizations when they lack either the internal capability or capacity for conducting certain work as well as when they require additional resources to bring products to market rapidly.
After reporting a successful start to FY16, Charles River expects continued success this year driven by customer demand and enhanced strategic partnerships, including expansion of its early stage portfolio.